以岭药业过敏性鼻炎一类新药芪防鼻通片进入国家医保

Core Insights - The National Medical Insurance Drug List for 2025 has been officially published, with Yiling Pharmaceutical's innovative drug Qifang Nasal Tablets being included for the first time [1] - Qifang Nasal Tablets are specifically indicated for the treatment of persistent allergic rhinitis, addressing a clinical gap in medication options [1] - The drug received approval from the National Medical Products Administration in January 2025 and was registered in Macau on July 12, 2025, marking it as the first innovative traditional Chinese medicine approved in Macau [1] Company Summary - Yiling Pharmaceutical has successfully developed and introduced Qifang Nasal Tablets, which are now part of the national medical insurance drug list [1] - The inclusion of this drug in the national insurance list is expected to enhance its market accessibility and potential sales [1] Industry Summary - The addition of Qifang Nasal Tablets to the national medical insurance drug list signifies a growing recognition and support for innovative traditional Chinese medicines within the healthcare system [1] - The approval and registration processes highlight the regulatory pathways for innovative drugs in both mainland China and Macau, indicating a potential trend for future drug developments in the industry [1]